FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289936801> ?p ?o ?g. }

• W4289936801 endingPage "1582" @default.
• W4289936801 startingPage "1573" @default.
• W4289936801 abstract "We have recently shown that coadministration of mAbs with anti-idiotypic distribution enhancers (AIDE) that inhibit mAb binding to tumor antigens enabled increased intratumoral mAb distribution and increased efficacy of an antibody-drug conjugate (trastuzumab emtansine, T-DM1). In this article, a pharmacokinetic/pharmacodynamic (PK/PD) model was applied to predict the impact of this optimization strategy on the within-tumor distribution and antitumor efficacy of trastuzumab-gelonin, where the released payload (gelonin) is expected to exhibit negligible bystander activity. Immunofluorescence histology was used to investigate trastuzumab-gelonin distribution in solid tumors following dosing with or without coadministration of anti-trastuzumab AIDEs. Antitumor efficacy of trastuzumab-gelonin, with or without coadministration of AIDEs, was also evaluated in tumor-bearing mice. Trastuzumab-gelonin efficiently induced cytotoxicity when applied to NCI-N87 cells in culture (IC50: 0.224 ± 0.079 nmol/L). PK/PD simulations predicted that anti-idiotypic single-domain antibodies AIDEs with dissociation rate constants between 0.03 and 0.2 per hour would provide optimal enhancement of trastuzumab-gelonin efficacy. LE8 and 1HE, anti-trastuzumab AIDEs, were selected for evaluation in vivo. Coadministration of trastuzumab-gelonin with the inhibitors increased the portion of tumor area that stained positive for trastuzumab-gelonin by 58% (P = 0.0059). In addition, LE8 or 1HE coadministration improved trastuzumab-gelonin efficacy in NCI-N87 xenograft-bearing mice by increasing the percent increase in life span (%ILS) from 27.8% (for trastuzumab-gelonin administered alone) to 62.5% when administered with LE8 (P = 0.0007) or 83.3% (P = 0.0007) when administered with 1HE. These findings support the hypothesis that transient, competitive inhibition of mAb-tumor binding can improve the intratumoral distribution and efficacy of immunotoxins when applied for treatment of solid tumors." @default.
• W4289936801 created "2022-08-06" @default.
• W4289936801 creator A5006940157 @default.
• W4289936801 creator A5047585385 @default.
• W4289936801 creator A5068031927 @default.
• W4289936801 creator A5080914054 @default.
• W4289936801 date "2022-08-05" @default.
• W4289936801 modified "2023-09-29" @default.
• W4289936801 title "Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin" @default.
• W4289936801 cites W1505534997 @default.
• W4289936801 cites W1549996850 @default.
• W4289936801 cites W1569531441 @default.
• W4289936801 cites W1980023938 @default.
• W4289936801 cites W1982114559 @default.
• W4289936801 cites W2001615040 @default.
• W4289936801 cites W2017543360 @default.
• W4289936801 cites W2021034379 @default.
• W4289936801 cites W2027269306 @default.
• W4289936801 cites W2029963293 @default.
• W4289936801 cites W2030953740 @default.
• W4289936801 cites W2032128112 @default.
• W4289936801 cites W2037248548 @default.
• W4289936801 cites W2081939392 @default.
• W4289936801 cites W2109545214 @default.
• W4289936801 cites W2114282952 @default.
• W4289936801 cites W2117884978 @default.
• W4289936801 cites W2119423559 @default.
• W4289936801 cites W2132059723 @default.
• W4289936801 cites W2134758761 @default.
• W4289936801 cites W2138460593 @default.
• W4289936801 cites W2158953356 @default.
• W4289936801 cites W2160272971 @default.
• W4289936801 cites W2162839084 @default.
• W4289936801 cites W2197484396 @default.
• W4289936801 cites W2290094801 @default.
• W4289936801 cites W2345914158 @default.
• W4289936801 cites W2398524420 @default.
• W4289936801 cites W2506631820 @default.
• W4289936801 cites W2761653596 @default.
• W4289936801 cites W2766798368 @default.
• W4289936801 cites W2773984687 @default.
• W4289936801 cites W2808185436 @default.
• W4289936801 cites W2884362356 @default.
• W4289936801 cites W2901988670 @default.
• W4289936801 cites W2922085672 @default.
• W4289936801 cites W2942836695 @default.
• W4289936801 cites W2942911318 @default.
• W4289936801 cites W2981672088 @default.
• W4289936801 cites W2999886821 @default.
• W4289936801 cites W3137681510 @default.
• W4289936801 cites W3139133115 @default.
• W4289936801 cites W3168908451 @default.
• W4289936801 cites W3187978533 @default.
• W4289936801 cites W3208087453 @default.
• W4289936801 cites W4213110115 @default.
• W4289936801 cites W4220889888 @default.
• W4289936801 doi "https://doi.org/10.1158/1535-7163.mct-22-0192" @default.
• W4289936801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35930739" @default.
• W4289936801 hasPublicationYear "2022" @default.
• W4289936801 type Work @default.
• W4289936801 citedByCount "4" @default.
• W4289936801 countsByYear W42899368012022 @default.
• W4289936801 countsByYear W42899368012023 @default.
• W4289936801 crossrefType "journal-article" @default.
• W4289936801 hasAuthorship W4289936801A5006940157 @default.
• W4289936801 hasAuthorship W4289936801A5047585385 @default.
• W4289936801 hasAuthorship W4289936801A5068031927 @default.
• W4289936801 hasAuthorship W4289936801A5080914054 @default.
• W4289936801 hasConcept C112705442 @default.
• W4289936801 hasConcept C115085202 @default.
• W4289936801 hasConcept C121608353 @default.
• W4289936801 hasConcept C126322002 @default.
• W4289936801 hasConcept C150903083 @default.
• W4289936801 hasConcept C159654299 @default.
• W4289936801 hasConcept C185592680 @default.
• W4289936801 hasConcept C203014093 @default.
• W4289936801 hasConcept C207001950 @default.
• W4289936801 hasConcept C2777325958 @default.
• W4289936801 hasConcept C2779786085 @default.
• W4289936801 hasConcept C530470458 @default.
• W4289936801 hasConcept C542903549 @default.
• W4289936801 hasConcept C71924100 @default.
• W4289936801 hasConcept C86803240 @default.
• W4289936801 hasConcept C98274493 @default.
• W4289936801 hasConceptScore W4289936801C112705442 @default.
• W4289936801 hasConceptScore W4289936801C115085202 @default.
• W4289936801 hasConceptScore W4289936801C121608353 @default.
• W4289936801 hasConceptScore W4289936801C126322002 @default.
• W4289936801 hasConceptScore W4289936801C150903083 @default.
• W4289936801 hasConceptScore W4289936801C159654299 @default.
• W4289936801 hasConceptScore W4289936801C185592680 @default.
• W4289936801 hasConceptScore W4289936801C203014093 @default.
• W4289936801 hasConceptScore W4289936801C207001950 @default.
• W4289936801 hasConceptScore W4289936801C2777325958 @default.
• W4289936801 hasConceptScore W4289936801C2779786085 @default.
• W4289936801 hasConceptScore W4289936801C530470458 @default.
• W4289936801 hasConceptScore W4289936801C542903549 @default.
• W4289936801 hasConceptScore W4289936801C71924100 @default.

• next